<DOC>
	<DOCNO>NCT00256880</DOCNO>
	<brief_summary>The purpose study determine effective safe new investigational drug treat patient relapsed refractory multiple myeloma . The treatment involve daily dose . A patient may continue receive treatment long benefiting treatment . Blood sample take specific time measure amount drug body specific time drug give . Blood sample also take lab test complete blood count clinical chemistry . Physical exam perform treatment . During treatment phase , patient undergo regular assessment safety clinical response .</brief_summary>
	<brief_title>Pazopanib ( GW786034 ) In Subjects With Relapsed Or Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Inclusion criterion : Must diagnosis relapse refractory multiple . bone marrow function [ ANC ( absolute neutrophil count ) great 1000/mm3 ] ; platelet count great equal 75,000/mm3 . renal function ( calculated creatinine clearance &gt; 50 mL.min , albumin less equal 500 mg ) . Exclusion criterion : Failed 3 prior line therapy include stem cell transplant . Females pregnant nursing . Unstable blood pressure . Significant heart condition history thrombosis . Any unstable , preexist major medical condition history cancer . Have receive investigational drug , chemotherapy , radiation treatment surgery within 28 day prior enter study .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pazopanib ( GW786034 )</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Myeloma</keyword>
</DOC>